FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2566433825> ?p ?o ?g. }

• W2566433825 endingPage "191" @default.
• W2566433825 startingPage "181" @default.
• W2566433825 abstract "Background Vascular-targeted photodynamic therapy, a novel tissue-preserving treatment for low-risk prostate cancer, has shown favourable safety and efficacy results in single-arm phase 1 and 2 studies. We compared this treatment with the standard of care, active surveillance, in men with low-risk prostate cancer in a phase 3 trial. Methods This randomised controlled trial was done in 47 European university centres and community hospitals. Men with low-risk, localised prostate cancer (Gleason pattern 3) who had received no previous treatment were randomly assigned (1:1) to vascular-targeted photodynamic therapy (4 mg/kg padeliporfin intravenously over 10 min and optical fibres inserted into the prostate to cover the desired treatment zone and subsequent activation by laser light 753 nm with a fixed power of 150 mW/cm for 22 min 15 s) or active surveillance. Randomisation was done by a web-based allocation system stratified by centre with balanced blocks of two or four patients. Best practice for active surveillance at the time of study design was followed (ie, biopsy at 12-month intervals and prostate-specific antigen measurement and digital rectal examination at 3-month intervals). The co-primary endpoints were treatment failure (histological progression of cancer from low to moderate or high risk or death during 24 months' follow-up) and absence of definite cancer (absence of any histology result definitely positive for cancer at month 24). Analysis was by intention to treat. Treatment was open-label, but investigators assessing primary efficacy outcomes were masked to treatment allocation. This trial is registered with ClinicalTrials.gov, number NCT01310894. Findings Between March 8, 2011, and April 30, 2013, we randomly assigned 206 patients to vascular-targeted photodynamic therapy and 207 patients to active surveillance. Median follow-up was 24 months (IQR 24–25). The proportion of participants who had disease progression at month 24 was 58 (28%) of 206 in the vascular-targeted photodynamic therapy group compared with 120 (58%) of 207 in the active surveillance group (adjusted hazard ratio 0·34, 95% CI 0·24–0·46; p<0·0001). 101 (49%) men in the vascular-targeted photodynamic therapy group had a negative prostate biopsy result at 24 months post treatment compared with 28 (14%) men in the active surveillance group (adjusted risk ratio 3·67, 95% CI 2·53–5·33; p<0·0001). Vascular-targeted photodynamic therapy was well tolerated. The most common grade 3–4 adverse events were prostatitis (three [2%] in the vascular-targeted photodynamic therapy group vs one [<1%] in the active surveillance group), acute urinary retention (three [2%] vs one [<1%]) and erectile dysfunction (two [1%] vs three [1%]). The most common serious adverse event in the vascular-targeted photodynamic therapy group was retention of urine (15 patients; severe in three); this event resolved within 2 months in all patients. The most common serious adverse event in the active surveillance group was myocardial infarction (three patients). Interpretation Padeliporfin vascular-targeted photodynamic therapy is a safe, effective treatment for low-risk, localised prostate cancer. This treatment might allow more men to consider a tissue-preserving approach and defer or avoid radical therapy. Funding Steba Biotech. Vascular-targeted photodynamic therapy, a novel tissue-preserving treatment for low-risk prostate cancer, has shown favourable safety and efficacy results in single-arm phase 1 and 2 studies. We compared this treatment with the standard of care, active surveillance, in men with low-risk prostate cancer in a phase 3 trial. This randomised controlled trial was done in 47 European university centres and community hospitals. Men with low-risk, localised prostate cancer (Gleason pattern 3) who had received no previous treatment were randomly assigned (1:1) to vascular-targeted photodynamic therapy (4 mg/kg padeliporfin intravenously over 10 min and optical fibres inserted into the prostate to cover the desired treatment zone and subsequent activation by laser light 753 nm with a fixed power of 150 mW/cm for 22 min 15 s) or active surveillance. Randomisation was done by a web-based allocation system stratified by centre with balanced blocks of two or four patients. Best practice for active surveillance at the time of study design was followed (ie, biopsy at 12-month intervals and prostate-specific antigen measurement and digital rectal examination at 3-month intervals). The co-primary endpoints were treatment failure (histological progression of cancer from low to moderate or high risk or death during 24 months' follow-up) and absence of definite cancer (absence of any histology result definitely positive for cancer at month 24). Analysis was by intention to treat. Treatment was open-label, but investigators assessing primary efficacy outcomes were masked to treatment allocation. This trial is registered with ClinicalTrials.gov, number NCT01310894. Between March 8, 2011, and April 30, 2013, we randomly assigned 206 patients to vascular-targeted photodynamic therapy and 207 patients to active surveillance. Median follow-up was 24 months (IQR 24–25). The proportion of participants who had disease progression at month 24 was 58 (28%) of 206 in the vascular-targeted photodynamic therapy group compared with 120 (58%) of 207 in the active surveillance group (adjusted hazard ratio 0·34, 95% CI 0·24–0·46; p<0·0001). 101 (49%) men in the vascular-targeted photodynamic therapy group had a negative prostate biopsy result at 24 months post treatment compared with 28 (14%) men in the active surveillance group (adjusted risk ratio 3·67, 95% CI 2·53–5·33; p<0·0001). Vascular-targeted photodynamic therapy was well tolerated. The most common grade 3–4 adverse events were prostatitis (three [2%] in the vascular-targeted photodynamic therapy group vs one [<1%] in the active surveillance group), acute urinary retention (three [2%] vs one [<1%]) and erectile dysfunction (two [1%] vs three [1%]). The most common serious adverse event in the vascular-targeted photodynamic therapy group was retention of urine (15 patients; severe in three); this event resolved within 2 months in all patients. The most common serious adverse event in the active surveillance group was myocardial infarction (three patients). Padeliporfin vascular-targeted photodynamic therapy is a safe, effective treatment for low-risk, localised prostate cancer. This treatment might allow more men to consider a tissue-preserving approach and defer or avoid radical therapy." @default.
• W2566433825 created "2017-01-06" @default.
• W2566433825 creator A5003957234 @default.
• W2566433825 creator A5004932066 @default.
• W2566433825 creator A5007357362 @default.
• W2566433825 creator A5010409135 @default.
• W2566433825 creator A5013864806 @default.
• W2566433825 creator A5019361384 @default.
• W2566433825 creator A5024919772 @default.
• W2566433825 creator A5026681845 @default.
• W2566433825 creator A5028350848 @default.
• W2566433825 creator A5028710627 @default.
• W2566433825 creator A5037670251 @default.
• W2566433825 creator A5043945139 @default.
• W2566433825 creator A5047473880 @default.
• W2566433825 creator A5050791373 @default.
• W2566433825 creator A5050891707 @default.
• W2566433825 creator A5059639992 @default.
• W2566433825 creator A5066054798 @default.
• W2566433825 creator A5066330818 @default.
• W2566433825 creator A5076511947 @default.
• W2566433825 creator A5079422188 @default.
• W2566433825 creator A5081426277 @default.
• W2566433825 creator A5083172675 @default.
• W2566433825 date "2017-02-01" @default.
• W2566433825 modified "2023-10-14" @default.
• W2566433825 title "Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial" @default.
• W2566433825 cites W1546940887 @default.
• W2566433825 cites W1965998918 @default.
• W2566433825 cites W1983145936 @default.
• W2566433825 cites W1991359895 @default.
• W2566433825 cites W2034203827 @default.
• W2566433825 cites W2039730458 @default.
• W2566433825 cites W2065520045 @default.
• W2566433825 cites W2086240335 @default.
• W2566433825 cites W2106869018 @default.
• W2566433825 cites W2107947132 @default.
• W2566433825 cites W2111288468 @default.
• W2566433825 cites W2143962930 @default.
• W2566433825 cites W2151929761 @default.
• W2566433825 cites W2154072446 @default.
• W2566433825 cites W2156070150 @default.
• W2566433825 cites W2174630668 @default.
• W2566433825 cites W2177883834 @default.
• W2566433825 cites W2336856317 @default.
• W2566433825 cites W2345581429 @default.
• W2566433825 cites W2786423272 @default.
• W2566433825 cites W2993539218 @default.
• W2566433825 doi "https://doi.org/10.1016/s1470-2045(16)30661-1" @default.
• W2566433825 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28007457" @default.
• W2566433825 hasPublicationYear "2017" @default.
• W2566433825 type Work @default.
• W2566433825 sameAs 2566433825 @default.
• W2566433825 citedByCount "245" @default.
• W2566433825 countsByYear W25664338252017 @default.
• W2566433825 countsByYear W25664338252018 @default.
• W2566433825 countsByYear W25664338252019 @default.
• W2566433825 countsByYear W25664338252020 @default.
• W2566433825 countsByYear W25664338252021 @default.
• W2566433825 countsByYear W25664338252022 @default.
• W2566433825 countsByYear W25664338252023 @default.
• W2566433825 crossrefType "journal-article" @default.
• W2566433825 hasAuthorship W2566433825A5003957234 @default.
• W2566433825 hasAuthorship W2566433825A5004932066 @default.
• W2566433825 hasAuthorship W2566433825A5007357362 @default.
• W2566433825 hasAuthorship W2566433825A5010409135 @default.
• W2566433825 hasAuthorship W2566433825A5013864806 @default.
• W2566433825 hasAuthorship W2566433825A5019361384 @default.
• W2566433825 hasAuthorship W2566433825A5024919772 @default.
• W2566433825 hasAuthorship W2566433825A5026681845 @default.
• W2566433825 hasAuthorship W2566433825A5028350848 @default.
• W2566433825 hasAuthorship W2566433825A5028710627 @default.
• W2566433825 hasAuthorship W2566433825A5037670251 @default.
• W2566433825 hasAuthorship W2566433825A5043945139 @default.
• W2566433825 hasAuthorship W2566433825A5047473880 @default.
• W2566433825 hasAuthorship W2566433825A5050791373 @default.
• W2566433825 hasAuthorship W2566433825A5050891707 @default.
• W2566433825 hasAuthorship W2566433825A5059639992 @default.
• W2566433825 hasAuthorship W2566433825A5066054798 @default.
• W2566433825 hasAuthorship W2566433825A5066330818 @default.
• W2566433825 hasAuthorship W2566433825A5076511947 @default.
• W2566433825 hasAuthorship W2566433825A5079422188 @default.
• W2566433825 hasAuthorship W2566433825A5081426277 @default.
• W2566433825 hasAuthorship W2566433825A5083172675 @default.
• W2566433825 hasBestOaLocation W25664338252 @default.
• W2566433825 hasConcept C121608353 @default.
• W2566433825 hasConcept C126322002 @default.
• W2566433825 hasConcept C141071460 @default.
• W2566433825 hasConcept C143998085 @default.
• W2566433825 hasConcept C168563851 @default.
• W2566433825 hasConcept C203092338 @default.
• W2566433825 hasConcept C2776235491 @default.
• W2566433825 hasConcept C2780101318 @default.
• W2566433825 hasConcept C2780192828 @default.
• W2566433825 hasConcept C2781406297 @default.
• W2566433825 hasConcept C71924100 @default.
• W2566433825 hasConceptScore W2566433825C121608353 @default.
• W2566433825 hasConceptScore W2566433825C126322002 @default.

• next